BidaskClub Lowers Xencor (XNCR) to Strong Sell

BidaskClub cut shares of Xencor (NASDAQ:XNCR) from a sell rating to a strong sell rating in a research report sent to investors on Friday.

Several other analysts have also issued reports on XNCR. ValuEngine upgraded shares of Xencor from a sell rating to a hold rating in a research report on Friday, September 1st. Canaccord Genuity set a $36.00 target price on shares of Xencor and gave the company a buy rating in a research report on Monday, October 23rd. Zacks Investment Research lowered shares of Xencor from a hold rating to a sell rating in a research report on Saturday, November 11th. Piper Jaffray Companies restated a buy rating and set a $35.00 target price on shares of Xencor in a research report on Sunday, November 12th. Finally, Cantor Fitzgerald initiated coverage on shares of Xencor in a research report on Wednesday, November 29th. They set an overweight rating and a $33.00 target price for the company. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of $30.80.

Shares of Xencor (NASDAQ XNCR) opened at $21.53 on Friday. Xencor has a 12-month low of $18.55 and a 12-month high of $28.64.

In other news, major shareholder John S. Stafford III purchased 24,653 shares of the stock in a transaction on Wednesday, October 25th. The shares were acquired at an average price of $20.01 per share, with a total value of $493,306.53. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder John S. Stafford III purchased 50,000 shares of the stock in a transaction on Thursday, November 2nd. The shares were purchased at an average cost of $19.58 per share, for a total transaction of $979,000.00. The disclosure for this purchase can be found here. Insiders have acquired 278,535 shares of company stock worth $5,526,936 in the last ninety days. Insiders own 4.03% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in XNCR. Dimensional Fund Advisors LP lifted its holdings in shares of Xencor by 57.4% in the first quarter. Dimensional Fund Advisors LP now owns 286,894 shares of the biopharmaceutical company’s stock worth $6,863,000 after buying an additional 104,638 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of Xencor in the first quarter worth $949,000. Bank of America Corp DE lifted its holdings in shares of Xencor by 144.4% in the first quarter. Bank of America Corp DE now owns 16,199 shares of the biopharmaceutical company’s stock worth $387,000 after buying an additional 9,572 shares in the last quarter. Strs Ohio lifted its holdings in shares of Xencor by 4.9% in the second quarter. Strs Ohio now owns 36,200 shares of the biopharmaceutical company’s stock worth $764,000 after buying an additional 1,700 shares in the last quarter. Finally, TD Asset Management Inc. lifted its holdings in shares of Xencor by 9.3% in the second quarter. TD Asset Management Inc. now owns 81,769 shares of the biopharmaceutical company’s stock worth $1,726,000 after buying an additional 6,963 shares in the last quarter. 77.62% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “BidaskClub Lowers Xencor (XNCR) to Strong Sell” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://sportsperspectives.com/2017/12/18/bidaskclub-lowers-xencor-xncr-to-strong-sell.html.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply